Revive Therapeutics Enters Exclusive License For Ganoderma Lucidum Intellectual Property

Revive Therapeutics (CSE: RVV) last night announced that it has has entered into an exclusive licensing agreement. The licensing agreement pertains to IP related to compounds of Ganoderma Lucidum, a form of a medicinal mushroom that has been found to have anticancer properties by the St. Jude Children’s Research Hospital.

The IP itself has been licensed from the Peurto Rico Science Technology and Research Trust, whom represents both St. Jude’s as well as Universidad Central del Caribe as it pertains to the licensing of intellectual property. Researchers from both the University and St. Jude’s worked together to discovery that compounds of the Ganoderma lucidum mushroom reportedly contain anti-cancer activity, which is said to been especially significant against forms of breast cancer.

Intellectual property licensed under the arrangement is held within an international patent, entitled “Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization.” Revive has gained the exclusive worldwide development and commercial rights related to the IP.

Ganoderma lucidum is a mushroom that has been used for millenia within traditional medicine. More recently, an extract of the mushroom that is commercially available is reportedly used in the prevention and treatment of cancer, immunological disorders and hypertension, with further ongoing researching presently suggesting it reduces the viability of breast cancer, while reducing tumor sizes by up to 50%, among other factors.

“We are very excited about the new addition to our clinical-stage product pipeline as part of our long-term strategy of unlocking the therapeutic potential of medicinal mushrooms such as psilocybin and Ganoderma lucidum to treat mental health, substance abuse and aggressive cancers. Our intention is to build off from the research conducted at St. Jude Children’s Research Hospital and UCC by advancing towards FDA IND-enabling studies to allow for human clinical studies.”

Michael Frank, CEO

Revive Therapeutics last traded at $0.42 on the CSE.

FULL DISCLOSURE: Revive Therapeutics is a former client of Canacom Group, the parent company of The Deep Dive. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply